Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: linagliptin; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Hypertension
Intervention:
Sponsors: Abbott; McKesson Canada
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Conditions: Diabetes Mellitus Type 2; Impaired Glucose Tolerance
Interventions: Drug: canakinumab + background diabetes therapy; Drug: placebo + background diabetes therapy
Sponsor: Novartis
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Type 2 Diabetes
Intervention: Behavioral: Motivational interviewing
Sponsor: University of Calgary
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 1 mg PF-04971729; Drug: 5 mg PF-04971729; Drug: 10 mg PF-04971729; Drug: 25 mg PF-04971729; Drug: 100 mg sitagliptin
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Type 2 Diabetes
Interventions: Dietary Supplement: low glycemic diet instruction; Dietary Supplement: high cereal fibre diet instruction
Sponsors: University of Toronto; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified February 2010
Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: Oxycodone controlled release (CR); Drug: Tapentadol extended release (ER)
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
Condition: Postprandial Lipaemia
Interventions: Dietary Supplement: Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola; Dietary Supplement: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter; Dietary Supplement: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter; Dietary Supplement: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter
Sponsors: University of British Columbia; Flax Council of Canada
Recruiting - verified February 2010
Condition: Diabetes Type 2
Interventions: Drug: BMS-770767; Drug: BMS-770767; Drug: BMS-770767; Drug: BMS-770767; Drug: Placebo; Drug: Metformin
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide once weekly; Drug: liraglutide
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2009
Condition: Diabetes Mellitus Type 2
Interventions: Drug: EGT0001442; Drug: Placebo capsules to match EGT0001442
Sponsor: Theracos
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: linagliptin low dose; Drug: placebo; Drug: linagliptin medium dose
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: INGAP Peptide; Drug: INGAP Peptide; Drug: Placebo
Sponsor: Exsulin Corporation
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo; Drug: Hydrochlorothiazide
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified December 2009
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: JNJ-28431754
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Hepatitis C
Intervention: Drug: Pegylated Interferons (Peg-IFN) and Ribavirin
Sponsors: University of Manitoba; Roche Pharma AG
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin + metformin; Drug: Linagliptin+metformin; Drug: Metformin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Cardiovascular Disease; Type 2 Diabetes Mellitus
Interventions: Drug: pioglitazone; Drug: placebo; Dietary Supplement: vitamin D; Dietary Supplement: placebo; Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Diabetic Neuropathies
Interventions: Drug: Carisbamate 800 mg/d; Drug: Pregabalin 300 mg/d; Drug: Placebo; Drug: Carisbamate 1,200 mg/d
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: RO4998452; Drug: RO4998452; Drug: RO4998452; Drug: RO4998452; Drug: RO4998452; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified February 2010
Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
Condition: Diabetic Foot Ulcer
Intervention: Drug: Fragmin
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: taspoglutide; Drug: placebo; Drug: pioglitazone; Drug: metformin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2189265; Drug: Sitagliptin 100mg, 24 months; Drug: Placebo solution; Drug: Placebo tablet, 6 months; Drug: Placebo tablet, 24 months; Drug: Sitagliptin 100 mg, 18 months
Sponsors: Eli Lilly and Company; United BioSource Corporation; Tessella Inc.; Berry Consultants
Recruiting - verified February 2010
Condition: Diabetic Foot Ulcer
Interventions: Drug: Fragmin/ Dalteparin Sodium; Drug: Placebo for Fragmin/ Dalteparin Sodium
Sponsor: Pfizer
Recruiting - verified February 2010
Conditions: Obesity; Gestational Diabetes; Type 2 Diabetes
Intervention: Behavioral: Exercise and dietary education
Sponsors: University of Manitoba; The Lawson Foundation
Recruiting - verified November 2009
Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Islet transplant; Drug: Belatacept; Drug: Daclizumab or Basiliximab; Drug: Mycophenolate Mofetil
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Otelixizumab
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation
Recruiting - verified June 2009
Condition: Arthritis, Rheumatoid
Intervention: Other: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
All Categories ... by Medical Condition » ... Diabetes » ... Canada 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
